1298 related articles for article (PubMed ID: 15213206)
41. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women.
Chlebowski RT; Anderson GL; Gass M; Lane DS; Aragaki AK; Kuller LH; Manson JE; Stefanick ML; Ockene J; Sarto GE; Johnson KC; Wactawski-Wende J; Ravdin PM; Schenken R; Hendrix SL; Rajkovic A; Rohan TE; Yasmeen S; Prentice RL;
JAMA; 2010 Oct; 304(15):1684-92. PubMed ID: 20959578
[TBL] [Abstract][Full Text] [Related]
42. Postmenopausal hormone therapy and change in mammographic density.
Greendale GA; Reboussin BA; Slone S; Wasilauskas C; Pike MC; Ursin G
J Natl Cancer Inst; 2003 Jan; 95(1):30-7. PubMed ID: 12509398
[TBL] [Abstract][Full Text] [Related]
43. Postmenopausal hormone therapy and cognitive outcomes: the Women's Health Initiative Memory Study (WHIMS).
Coker LH; Espeland MA; Rapp SR; Legault C; Resnick SM; Hogan P; Gaussoin S; Dailey M; Shumaker SA
J Steroid Biochem Mol Biol; 2010 Feb; 118(4-5):304-10. PubMed ID: 19932751
[TBL] [Abstract][Full Text] [Related]
44. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial.
LaCroix AZ; Chlebowski RT; Manson JE; Aragaki AK; Johnson KC; Martin L; Margolis KL; Stefanick ML; Brzyski R; Curb JD; Howard BV; Lewis CE; Wactawski-Wende J;
JAMA; 2011 Apr; 305(13):1305-14. PubMed ID: 21467283
[TBL] [Abstract][Full Text] [Related]
45. Women's Health Initiative clinical trials: potential interactive effect of calcium and vitamin D supplementation with hormonal therapy on cardiovascular disease.
Jiang X; Nudy M; Aragaki AK; Robbins JA; Manson JE; Stefanick ML; OʼSullivan DM; Shikany JM; LeBlanc ES; Kelsey AM; Cauley J; Martin LW; Payne ME; Johnson KC; Howard B; Schnatz PF
Menopause; 2019 Aug; 26(8):841-849. PubMed ID: 31145202
[TBL] [Abstract][Full Text] [Related]
46. Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate.
Pickar JH; Yeh I; Wheeler JE; Cunnane MF; Speroff L
Fertil Steril; 2001 Jul; 76(1):25-31. PubMed ID: 11438315
[TBL] [Abstract][Full Text] [Related]
47. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.
Rossouw JE; Anderson GL; Prentice RL; LaCroix AZ; Kooperberg C; Stefanick ML; Jackson RD; Beresford SA; Howard BV; Johnson KC; Kotchen JM; Ockene J;
JAMA; 2002 Jul; 288(3):321-33. PubMed ID: 12117397
[TBL] [Abstract][Full Text] [Related]
48. Brain volumes, cognitive impairment, and conjugated equine estrogens.
Espeland MA; Tindle HA; Bushnell CA; Jaramillo SA; Kuller LH; Margolis KL; Mysiw WJ; Maldjian JA; Melhem ER; Resnick SM;
J Gerontol A Biol Sci Med Sci; 2009 Dec; 64(12):1243-50. PubMed ID: 19729392
[TBL] [Abstract][Full Text] [Related]
49. Lung cancer among postmenopausal women treated with estrogen alone in the women's health initiative randomized trial.
Chlebowski RT; Anderson GL; Manson JE; Schwartz AG; Wakelee H; Gass M; Rodabough RJ; Johnson KC; Wactawski-Wende J; Kotchen JM; Ockene JK; O'Sullivan MJ; Hubbell FA; Chien JW; Chen C; Stefanick ML
J Natl Cancer Inst; 2010 Sep; 102(18):1413-21. PubMed ID: 20709992
[TBL] [Abstract][Full Text] [Related]
50. Menopausal hormone therapy and risks of melanoma and nonmelanoma skin cancers: women's health initiative randomized trials.
Tang JY; Spaunhurst KM; Chlebowski RT; Wactawski-Wende J; Keiser E; Thomas F; Anderson ML; Zeitouni NC; Larson JC; Stefanick ML
J Natl Cancer Inst; 2011 Oct; 103(19):1469-75. PubMed ID: 21878677
[TBL] [Abstract][Full Text] [Related]
51. Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on endometrial bleeding.
Archer DF; Dorin M; Lewis V; Schneider DL; Pickar JH
Fertil Steril; 2001 Jun; 75(6):1080-7. PubMed ID: 11384630
[TBL] [Abstract][Full Text] [Related]
52. Associations of Hearing Loss and Menopausal Hormone Therapy With Change in Global Cognition and Incident Cognitive Impairment Among Postmenopausal Women.
Armstrong NM; Espeland MA; Chen JC; Masaki K; Wactawski-Wende J; Li W; Gass MLS; Stefanick ML; Manson JE; Deal JA; Rapp SR; Lin FR; Resnick SM
J Gerontol A Biol Sci Med Sci; 2020 Feb; 75(3):537-544. PubMed ID: 31326978
[TBL] [Abstract][Full Text] [Related]
53. Menopausal Hormone Therapy and Risks of First Hospitalized Heart Failure and its Subtypes During the Intervention and Extended Postintervention Follow-up of the Women's Health Initiative Randomized Trials.
Liu L; Klein L; Eaton C; Panjrath G; Martin LW; Chae CU; Greenland P; Lloyd-Jones DM; Wactawski-Wende J; Manson JE
J Card Fail; 2020 Jan; 26(1):2-12. PubMed ID: 31536806
[TBL] [Abstract][Full Text] [Related]
54. The effect of tibolone and continuous combined conjugated equine oestrogens plus medroxyprogesterone acetate on progression of carotid intima-media thickness: the Osteoporosis Prevention and Arterial effects of tiboLone (OPAL) study.
Bots ML; Evans GW; Riley W; McBride KH; Paskett ED; Helmond FA; Grobbee DE;
Eur Heart J; 2006 Mar; 27(6):746-55. PubMed ID: 16415304
[TBL] [Abstract][Full Text] [Related]
55. The Postmenopausal Estrogen/Progestin Interventions Study: primary outcomes in adherent women.
Barrett-Connor E; Slone S; Greendale G; Kritz-Silverstein D; Espeland M; Johnson SR; Waclawiw M; Fineberg SE
Maturitas; 1997 Jul; 27(3):261-74. PubMed ID: 9288699
[TBL] [Abstract][Full Text] [Related]
56. Menopausal hormone therapy and the incidence of carpal tunnel syndrome in postmenopausal women: Findings from the Women's Health Initiative.
Al-Rousan T; Sparks JA; Pettinger M; Chlebowski R; Manson JE; Kauntiz AM; Wallace R
PLoS One; 2018; 13(12):e0207509. PubMed ID: 30513095
[TBL] [Abstract][Full Text] [Related]
57. Effects of postmenopausal hormone therapy on incident atrial fibrillation: the Women's Health Initiative randomized controlled trials.
Perez MV; Wang PJ; Larson JC; Virnig BA; Cochrane B; Curb JD; Klein L; Manson JE; Martin LW; Robinson J; Wassertheil-Smoller S; Stefanick ML
Circ Arrhythm Electrophysiol; 2012 Dec; 5(6):1108-16. PubMed ID: 23169946
[TBL] [Abstract][Full Text] [Related]
58. New evidence regarding hormone replacement therapies is urgently required transdermal postmenopausal hormone therapy differs from oral hormone therapy in risks and benefits.
Modena MG; Sismondi P; Mueck AO; Kuttenn F; Lignières Bd; Verhaeghe J; Foidart JM; Caufriez A; Genazzani AR;
Maturitas; 2005 Sep; 52(1):1-10. PubMed ID: 15963666
[TBL] [Abstract][Full Text] [Related]
59. Estrogen metabolism in menopausal hormone users in the women's health initiative observational study: Does it differ between estrogen plus progestin and estrogen alone?
Falk RT; Manson JE; Barnabei VM; Anderson GL; Brinton LA; Rohan TE; Cauley JA; Chen C; Coburn SB; Pfeiffer RM; Reding KW; Sarto GE; Wentzensen N; Chlebowski RT; Xu X; Trabert B
Int J Cancer; 2019 Feb; 144(4):730-740. PubMed ID: 30183089
[TBL] [Abstract][Full Text] [Related]
60. Women's Health Initiative estrogen plus progestin clinical trial: a study that does not allow establishing relevant clinical risks.
Aedo S; Cavada G; Blümel JE; Chedraui P; Fica J; Barriga P; Brantes S; Irribarra C; Vallejo M; Campodónico Í
Menopause; 2015 Dec; 22(12):1317-22. PubMed ID: 25968833
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
